BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid tumors REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed with BDC-3042 in the single-agent dose-escalation portion of this first-in-human Phase 1/2 clinical study.

BDC-3042是一种刺激先天免疫系统的新型Dectin-2激动性抗体，正在进行1/2期剂量递增和扩增研究，用于广泛实体瘤患者REDWOOD CITY，CA，10月17日2023年（GLOBE NEWSWIRE）-博尔特生物治疗公司（纳斯达克股票代码：博尔特），一家开发用于治疗癌症的新型免疫疗法的临床阶段生物制药公司今天宣布，第一名患者已在该首次人体1/2期临床研究的单药剂量递增部分中给予BDC-3042。

The study will evaluate BDC-3042 in patients with metastatic or unresectable triple-negative breast cancer (TNBC), colorectal cancer, clear cell renal cell carcinoma, head and neck cancer, non-small cell lung cancer (NSCLC), or ovarian cancer. “We are excited to have dosed the first patient in this first-in-human clinical trial, which will evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of BDC-3042 in a diverse set of advanced cancers,” said Edith A.

该研究将评估转移性或不可切除的三阴性乳腺癌（TNBC），结直肠癌，透明细胞肾细胞癌，头颈癌，非小细胞肺癌（NSCLC）或卵巢癌患者的BDC-3042癌症。“我们很高兴在这项首次人体临床试验中为第一位患者服药，这将评估BDC-3042在多种晚期癌症中的安全性，药代动力学，药效学和抗肿瘤活性，”Edith a.说。

Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. “BDC-3042 is a monoclonal antibody that repolarizes tumor-associated macrophages (TAMs) to attack tumor cells and is the first-in-class Dectin-2 agonist. As Dectin-2 gene expression is elevated in TAMs across a broad range of solid tumor types, we see potential for this novel immunotherapy to be used for a wide range of cancers.

Perez，M.D.，Bolt Biotherapeutics的首席医疗官。“BDC-3042是一种单克隆抗体，可使肿瘤相关巨噬细胞（TAMs）重新极化以攻击肿瘤细胞，是一流的Dectin-2激动剂。由于Dectin-2基因表达在TAMs中广泛存在于实体瘤中类型，我们看到这种新型免疫疗法可用于广泛的癌症。

We are enthusiastic to advance our second innovative immunotherapy program to the clinic with a focus on providing breakthroughs for patients.” “TAMs are a major component of the immune infiltrate in most cancers and play a key role in establishing an immunosuppressive tumor microenvironment that enables tumor progression,” explained Shelley Ackerman, P.

我们热衷于将我们的第二项创新免疫治疗计划推向临床，重点是为患者提供突破。”Shelley-Ackerman，P.解释说：“TAMs是大多数癌症中免疫浸润的主要成分，在建立能够促进肿瘤进展的免疫抑制性肿瘤微环境中发挥关键作用。